Axi-Cel (anti-CD19 CAR T-cell therapy FMC63-28Z) Induces Durable Remissions in Relapsed CLL, B-Cell Lymphoma

[AussieNeil]

Patients with relapsed chronic lymphocytic leukemia (CLL) and B-cell lymphoma who received the anti-CD19 CAR T-cell therapy FMC63-28Z, which was later developed as axicabtagene ciloleucel (axi-cel; Yescarta), experienced highly durable rates of remission, according to long-term data from a phase 1/2 study (NCT00924326)

Results from the study, which were presented at the 2020 ASCO Virtual Scientific Program, showed that 58% of the CD19-directed CAR T-cell product treatments (n = 25/43) led to a best response of complete remission (CR), while 23% (n = 10/43) resulted in a best response of partial remission (PR). No patients who achieved a best response of PR or stable disease experienced a durable response. Furthermore, 60% of the CRs were determined to still be evaluable and ongoing at the time of the last follow-up. For the ongoing CRs, the duration of response (DOR) ranged from 42 months to 113 months.

onclive.com/view/axi-cel-in...

This is an unlocked post: healthunlocked.com/cllsuppo...

[Sushibruno]

I wish they had a magic pill to put it to sleep for decades.. even if it's not a cure... I wouldn't be feeling so anxious like it just hit me now.....( not because of this post Neil bc I get like this from time to time) I just can't handle that I have this. Im sorry...... beautiful flowers as always, they bring me peace.

[Sushibruno]

Thank you😊

[bennevisplace]

Good results considering many of the patients in the study had aggressive lymphomas. Only 7/43 had CLL.

[Fran57]

Thanks, as always, Neil, for the information. Always good to hear of even more promising treatment.

Fran 😉

[Smakwater]

Started recruiting in 2009. 10 arms and pretreat with chemo. Trial looked to be very complex, long term, and pre novel era criteria.

The take away that caught my interest was the 97 month response for DLBCL.

JM